HC Wainwright reiterated their buy rating on shares of Acer Therapeutics (NASDAQ:ACER – Get Rating) in a report released on Tuesday morning, Marketbeat.com reports. HC Wainwright currently has a $12.00 target price on the biopharmaceutical company’s stock. Separately, Zacks Investment Research cut shares of Acer Therapeutics from a buy rating to a hold rating in […]
Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions Targeting a pre-NDA meeting with FDA in Q2 2021
February 11, 2021 08:30 ET | Source: Acer Therapeutics Inc. Acer Therapeutics Inc. Newton, Massachusetts, UNITED STATES
NEWTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced topline results from its bioequivalence trial in which ACER-001 showed similar relative bioavailability compared to BUPHENYL® (sodium phenylbutyrate) under fed conditions. ACER-001 powder is a proprietary, taste-masked, immediate release formulation of sodium phenylbutyrate (NaPB) in development for the treatment of various inborn errors